Drug intelligence / Profile preview

clomiphene + fluticasone furoate + ethinyl estradiol

Development stage: Unknown
Lead developer: Procter & Gamble
Modality: Small Molecules
Administration: Oral, Inhalation, Intranasal

Overview

This is a combination medication containing clomiphene (an ovulatory stimulant), fluticasone furoate (a corticosteroid), and ethinyl estradiol (a synthetic estrogen). Clomiphene is used to induce ovulation in women with infertility, working similarly to estrogen to stimulate egg development and release. Ethinyl estradiol is a synthetic estrogen that can reverse the deleterious effects of clomiphene on endometrial thickness, potentially contributing to higher pregnancy rates. Fluticasone furoate is a corticosteroid typically used for respiratory conditions.

Targets

ESR1 (ERα)ESR2 (ERβ)

Beyond the preview

Go deeper on clomiphene + fluticasone furoate + ethinyl estradiol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on clomiphene + fluticasone furoate + ethinyl estradiol.

Explore the full profile